Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3/2020

01-09-2020 | Breast Cancer

Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases

Authors: Rakesh Kumar, Aswathy Mary Paul, Ravikumar Amjesh, Bijesh George, M. Radhakrishna Pillai

Published in: Cancer and Metastasis Reviews | Issue 3/2020

Login to get access

Abstract

Most epithelial cancer types are polygenic in nature and are driven by coordinated dysregulation of multiple regulatory pathways, genes, and protein modifications. The process of coordinated regulation of cancer promoting pathways in response to extrinsic and intrinsic signals facilitates the dysregulation of several pathways with complementary functions, contributing to the hallmarks of cancer. Dysregulation and hyperactivation of cell surface human epidermal growth factor receptors (HERs) and cytoskeleton remodeling by p21-activated kinases (PAKs) are two prominent interconnected aspects of oncogenesis. We briefly discuss the discoveries and significant advances in the area of coordinated regulation of HERs and PAKs in the development and progression of breast and other epithelial cancers. We also discuss how initial studies involving heregulin signaling via HER3-HER2 axis and HER2-overexpressing breast cancer cells not only discovered a mechanistic role of PAK1 in breast cancer pathobiology but also acted as a bridge in generating a broader cancer research interest in other PAK family members and cancer types and catalyzed establishing the role of PAKs in human cancer, at-large. In addition, growth factor stimulation of the PAK pathway also helped to recognize new facets of PAKs, connecting the PAK pathway to oncogenesis, nuclear signaling, gene expression, mitotic progression, DNA damage response, among other phenotypic responses, and shaped the field of PAK cancer research. Finally, we recount some of the current limitations of HER- and PAK-directed therapeutics in counteracting acquired therapeutic resistance and discuss how cancer’s as a polygenic disease may be best targeted with a polygenic approach.
Literature
1.
Ghosh, S., Marrocco, I., & Yarden, Y. (2020). Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research, 147, 1–57.PubMed
2.
Chen, M.-K., Hsu, J. L., & Hung, M.-C. (2020). Nuclear receptor tyrosine kinase transport and functions in cancer. Advances in Cancer Research, 147, 59–107.PubMed
3.
Kumar, R., George, B., Campbell, M. R., Verma, N., Paul, A. M., Melo-Alvim, C., Ribeiro, L., Pillai, M. R., Marques da Costa, L., & Moasser, M. M. (2020). HER family in cancer progression: From discovery to 2020 and beyond. Advances in Cancer Research, 147, 109–152.PubMed
4.
Kumar, R., & Mendelsohn, J. (1991). Polypeptide growth factors in the regulation of human tumor cell proliferation. Current Opinion in Oncology, 3(1), 70–74.PubMed
5.
Mendelsohn, J. (2000). Blockade of receptors for growth factors: An anticancer therapy - the Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clinical Cancer Research, 6(3), 747–753.PubMed
6.
Kumar, R. (2001). Targeting epidermal growth factor receptor family members for treatment of breast cancer. Biological Therapy of Breast Cancer, 3, 3–6.
7.
Kumar, R., de Vijver, Van, M., Tortora, G., Ciardiello, F., Goldkorn, T., Miller, W. H., & Norton, L. (2019). A tribute to John Mendelsohn: A pioneer in targeted cancer therapy. Cancer Research, 79(17), 4315–4323.PubMed
8.
Kumar, R., & Vadlamudi, R. K. (2002). Emerging functions of p21-activated kinases in human cancer cells. Journal of Cellular Physiology, 193(2), 133–144.PubMed
9.
Gururaj, A. E., Rayala, S. K., & Kumar, R. (2005). p21-activated kinase signaling in breast cancer. Breast Cancer Research : BCR, 7(1), 5–12.PubMed
10.
Kumar, R., Gururaj, A. E., & Barnes, C. J. (2006). p21-activated kinases in cancer. Nature Reviews. Cancer, 6(6), 459–471.PubMed
11.
Molli, P. R., Li, D. Q., Murray, B. W., Rayala, S. K., & Kumar, R. (2009). PAK signaling in oncogenesis. Oncogene, 28(28), 2545–2555.PubMedPubMedCentral
12.
Kumar, R., & Li, D.-Q. (2016). PAKs in human Cancer progression: From inception to cancer therapeutic to future oncobiology. Advances in Cancer Research, 130, 137–209.PubMed
13.
Kumar, R., Sanawar, R., Li, X., & Li, F. (2017). Structure, biochemistry, and biology of PAK kinases. Gene, 605, 20–31.PubMed
14.
Cohen, S. (1962). Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. The Journal of Biological Chemistry, 237, 1555–1562.PubMed
15.
Carpenter, G., King Jr., L., & Cohen, S. (1978). Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature, 276(5686), 409–410.PubMed
16.
Carpenter, G., King Jr., L., & Cohen, S. (1979). Rapid enhancement of protein phosphorylation in A-431 cell membrane preparations by epidermal growth factor. The Journal of Biological Chemistry, 254(11), 4884–4891.PubMed
17.
Cohen, S., Carpenter, G., & King Jr., L. (1980). Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. The Journal of Biological Chemistry, 255(10), 4834–4842.PubMed
18.
Semba, K., Kamata, N., Toyoshima, K., & Yamamoto, T. (1985). A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 82(19), 6497–6501.PubMedPubMedCentral
19.
Schechter, A. L., Hung, M. C., Vaidyanathan, L., Weinberg, R. A., Yang-Feng, T. L., Francke, U., et al. (1985). The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science (New York, N.Y.), 229(4717), 976–978.
20.
Hung, M. C., Schechter, A. L., Chevray, P. Y., Stern, D. F., & Weinberg, R. A. (1986). Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles. Proceedings of the National Academy of Sciences of the United States of America, 83(2), 261–264.PubMedPubMedCentral
21.
van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., & Nusse, R. (1988). Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. The New England Journal of Medicine, 319(19), 1239–1245.PubMed
22.
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, N.Y.), 244(4905), 707–712.
23.
Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., & Aaronson, S. A. (1989). Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proceedings of the National Academy of Sciences of the United States of America, 86(23), 9193–9197.PubMedPubMedCentral
24.
Plowman, G. D., Whitney, G. S., Neubauer, M. G., Green, J. M., McDonald, V. L., Todaro, G. J., & Shoyab, M. (1990). Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proceedings of the National Academy of Sciences of the United States of America, 87(13), 4905–4909.PubMedPubMedCentral
25.
Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., et al. (1993). Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proceedings of the National Academy of Sciences of the United States of America, 90(5), 1746–1750.PubMedPubMedCentral
26.
Earp 3rd, H. S., Calvo, B. F., & Sartor, C. I. (2003). The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Transactions of the American Clinical and Climatological Association, 114, 315–334.PubMedPubMedCentral
27.
Jones, F. E. (2008). HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. Journal of Mammary Gland Biology and Neoplasia, 13(2), 247–258.PubMedPubMedCentral
28.
Pines, G., Köstler, W. J., & Yarden, Y. (2010). Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy. FEBS Letters, 584(12), 2699–2706.PubMedPubMedCentral
29.
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science (New York, N.Y.), 304(5676), 1497–1500.
30.
Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., et al. (2006). Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Research, 66(16), 8163–8171.PubMed
31.
Zhang, K., Cui, J., Xi, H., Bian, S., Ma, L., Shen, W., et al. (2015). Serum HER2 is a potential surrogate for tissue HER2 status in gastric cancer: A systematic review and meta-analysis. PLoS One, 10(8), e0136322–e0136322.PubMedPubMedCentral
32.
Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., et al. (2019). Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell, 36(4), 444–457.e7.PubMed
33.
Wang, Z. (2017). ErbB receptors and cancer. Methods in Molecular Biology (Clifton, N.J.), 1652, 3–35.
34.
Baulida, J., Kraus, M. H., Alimandi, M., Di Fiore, P. P., & Carpenter, G. (1996). All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. The Journal of Biological Chemistry, 271(9), 5251–5257.PubMed
35.
Haslekås, C., Breen, K., Pedersen, K. W., Johannessen, L. E., Stang, E., & Madshus, I. H. (2005). The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Molecular Biology of the Cell, 16(12), 5832–5842.PubMedPubMedCentral
36.
Sorkin, A., & von Zastrow, M. (2009). Endocytosis and signalling: Intertwining molecular networks. Nature Reviews. Molecular and Cellular Biology, 10(9), 609–622.
37.
Pedersen, N. M., Madshus, I. H., Haslekås, C., & Stang, E. (2008). Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Molecular Cancer Research : MCR, 6(3), 491–500.PubMed
38.
Peschard, P., & Park, M. (2003). Escape from Cbl-mediated downregulation: A recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell, 3(6), 519–523.PubMed
39.
Pietilä, M., Sahgal, P., Peuhu, E., Jäntti, N. Z., Paatero, I., Närvä, E., et al. (2019). SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nature Communications, 10(1), 2340.PubMedPubMedCentral
40.
Wiley, H. S. (2003). Trafficking of the ErbB receptors and its influence on signaling. Experimental Cell Research, 284(1), 78–88.PubMed
41.
Waterman, H., Alroy, I., Strano, S., Seger, R., & Yarden, Y. (1999). The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. The EMBO Journal, 18(12), 3348–3358.PubMedPubMedCentral
42.
Stern, D. F., & Kamps, M. P. (1988). EGF-stimulated tyrosine phosphorylation of p185neu: A potential model for receptor interactions. The EMBO Journal, 7(4), 995–1001.PubMedPubMedCentral
43.
King, C. R., Borrello, I., Bellot, F., Comoglio, P., & Schlessinger, J. (1988). Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. The EMBO Journal, 7(6), 1647–1651.PubMedPubMedCentral
44.
Wada, T., Qian, X. L., & Greene, M. I. (1990). Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell, 61(7), 1339–1347.PubMed
45.
Goldman, R., Levy, R. B., Peles, E., & Yarden, Y. (1990). Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation. Biochemistry, 29(50), 11024–11028.PubMed
46.
Ferguson, K. M. (2008). Structure-based view of epidermal growth factor receptor regulation. Annual Review of Biophysics, 37, 353–373.PubMedPubMedCentral
47.
Linggi, B., & Carpenter, G. (2006). ErbB receptors: New insights on mechanisms and biology. Trends in Cell Biology, 16(12), 649–656.PubMed
48.
Jones, R. B., Gordus, A., Krall, J. A., & MacBeath, G. (2006). A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature, 439(7073), 168–174.PubMed
49.
Schulze, W. X., Deng, L., & Mann, M. (2005). Phosphotyrosine interactome of the ErbB-receptor kinase family. Molecular Systems Biology, 1, 2005.0008–2005.0008.PubMedPubMedCentral
50.
Sweeney, C., Fambrough, D., Huard, C., Diamonti, A. J., Lander, E. S., Cantley, L. C., & Carraway 3rd, K. L. (2001). Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. The Journal of Biological Chemistry, 276(25), 22685–22698.PubMed
51.
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983). Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 80(5), 1337–1341.PubMedPubMedCentral
52.
Van de Vijver, M. J., Kumar, R., & Mendelsohn, J. (1991). Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. The Journal of Biological Chemistry, 266(12), 7503–7508.PubMed
53.
Mendelsohn, J. (2000). Jeremiah Metzger Lecture. Targeted cancer therapy. Transactions of the American Clinical and Climatological Association, 111, 95–111.PubMedPubMedCentral
54.
Mendelsohn, J., Prewett, M., Rockwell, P., & Goldstein, N. I. (2015). CCR 20th anniversary commentary: A chimeric antibody, C225, inhibits EGFR activation and tumor growth. In Clinical cancer research : An official journal of the American Association for Cancer Research. United: States.
55.
Kumar, R., Murad, F., Bogler, O., O’Malley, B. W., & Hortobagyi, G. N. (2019). John Mendelsohn: A visionary scientist, oncologist and leader. Genes & Cancer, 10(5–6), 109–118.
56.
Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D., & Lippman, M. E. (1990). Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (New York, N.Y.), 249(4976), 1552–1555.
57.
Kumar, R., Shepard, H. M., & Mendelsohn, J. (1991). Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Molecular and Cellular Biology, 11(2), 979–986.PubMedPubMedCentral
58.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., et al. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 89(10), 4285–4289.PubMedPubMedCentral
59.
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., et al. (1999). Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in Oncology, 26(4 Suppl 12), 78–83.PubMed
60.
Adam, L., Vadlamudi, R., Kondapaka, S. B., Chernoff, J., Mendelsohn, J., & Kumar, R. (1998). Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. The Journal of Biological Chemistry, 273(43), 28238–28246.PubMed
61.
Kumar, R. (2007). ErbB-dependent signaling as a determinant of trastuzumab resistance. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 13(16), 4657–4659.
62.
Mills, G. B., & Yarden, Y. (2010). The rebirth of a phoenix: Ovarian cancers are addicted to ErbB-3. Cancer Cell, 17(3), 217–218.PubMed
63.
Morrison, M. M., Hutchinson, K., Williams, M. M., Stanford, J. C., Balko, J. M., Young, C., et al. (2013). ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. The Journal of Clinical Investigation, 123(10), 4329–4343.PubMedPubMedCentral
64.
Wang, S., Huang, J., Lyu, H., Lee, C.-K., Tan, J., Wang, J., & Liu, B. (2013). Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death & Disease, 4(3), e556–e556.
65.
Li, X., Xu, Y., Ding, Y., Li, C., Zhao, H., Wang, J., & Meng, S. (2018). Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer. Molecular Cancer, 17(1), 113.PubMedPubMedCentral
66.
Kennedy, S. P., Han, J. Z. R., Portman, N., Nobis, M., Hastings, J. F., Murphy, K. J., et al. (2019). Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. Breast Cancer Research, 21(1), 43.PubMed
67.
Cytoskeleton Signaling in Cancer, Editors - Kumar, R. and Hall, A. (2009). Cancer. Metastasis Reviews, 28(1–2), 1–263.
68.
Manser, E., Leung, T., Salihuddin, H., Zhao, Z. S., & Lim, L. (1994). A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature, 367(6458), 40–46.PubMed
69.
Galisteo, M. L., Chernoff, J., Su, Y. C., Skolnik, E. Y., & Schlessinger, J. (1996). The adaptor protein Nck links receptor tyrosine kinases with the serine-threonine kinase Pak1. The Journal of Biological Chemistry, 271(35), 20997–201000.PubMed
70.
Bekri, S., Adélaïde, J., Merscher, S., Grosgeorge, J., Caroli-Bosc, F., Perucca-Lostanlen, D., et al. (1997). Detailed map of a region commonly amplified at 11q13➔q14 in human breast carcinoma. Cytogenet Cell Genet., 79(1–2), 125–131. Methods in Molecular Biology. N.J: Clifton.
71.
Adam, L., Vadlamudi, R., Mandal, M., Chernoff, J., & Kumar, R. (2000). Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. The Journal of Biological Chemistry., 275(16), 12041–12050.PubMed
72.
Vadlamudi, R. K., Adam, L., Wang, R. A., Mandal, M., Nguyen, D., Sahin, A., et al. (2000). Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. The Journal of Biological Chemistry, 275(46), 36238–36244.PubMed
73.
Bagheri-Yarmand, R., Mandal, M., Taludker, A. H., Wang, R. A., Vadlamudi, R. K., Kung, H. J., & Kumar, R. (2001). Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. The Journal of Biological Chemistry., 276(31), 29403–29409.PubMed
74.
Oladimeji, P., Skerl, R., Rusch, C., & Diakonova, M. (2016). Synergistic activation of ERα by estrogen and prolactin in breast cancer cells requires tyrosyl phosphorylation of PAK1. Cancer Research, 76(9), 2600–2611.PubMedPubMedCentral
75.
Li, F., Adam, L., Vadlamudi, R. K., Zhou, H., Sen, S., Chernoff, J., & Kumar, R. (2002). p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Reports, 3(8), 767–773.PubMedPubMedCentral
76.
Singh, R. R., Song, C., Yang, Z., & Kumar, R. (2005). Nuclear localization and chromatin targets of p21-activated kinase 1. The Journal of Biological Chemistry, 280(18), 18130–18137.PubMed
77.
Cotteret, S., & Chernoff, J. (2005). Pak GITs to Aurora-A. Developmental Cell, 9(5), 573–574.PubMed
78.
Wang, R.-A., Vadlamudi, R. K., Bagheri-Yarmand, R., Beuvink, I., Hynes, N. E., & Kumar, R. (2003). Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. The Journal of Cell Biology, 161(3), 583–592.PubMedPubMedCentral
79.
Wang, R.-A., Mazumdar, A., Vadlamudi, R. K., & Kumar, R. (2002). P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. The EMBO Journal, 21(20), 5437–5447.PubMedPubMedCentral
80.
Wang, R.-A., Zhang, H., Balasenthil, S., Medina, D., & Kumar, R. (2006). PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene, 25(20), 2931–2936.PubMed
81.
Holm, C., Rayala, S., Jirström, K., Stål, O., Kumar, R., & Landberg, G. (2006). Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. Journal of the National Cancer Institute, 98(10), 671–680.PubMed
82.
Rayala, S. K., Molli, P. R., & Kumar, R. (2006). Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Research, 66(12), 5985–5988.PubMed
83.
Jordan, V. C. (2006). Pak up your breast tumor--and grow! Journal of the National Cancer. United States: Institute.
84.
Kumar, R., & Hung, M.-C. (2005). Signaling intricacies take center stage in cancer cells. Cancer Research, 65(7), 2511–2515.PubMed
85.
Kumar, R., Deivendran, S., Santhosh Kumar, T. R., & Pillai, M. R. (2017). Signaling coupled epigenomic regulation of gene expression. Oncogene, 36(43), 5917–5926.PubMed
86.
Balasenthil, S., Barnes, C. J., Rayala, S. K., & Kumar, R. (2004). Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Letters, 567(2–3), 243–247.
87.
Balasenthil, S., Sahin, A. A., Barnes, C. J., Wang, R.-A., Pestell, R. G., Vadlamudi, R. K., & Kumar, R. (2004). p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. The Journal of Biological Chemistry, 279(2), 1422–1428.PubMed
88.
Tharakan, R., Lepont, P., Singleton, D., Kumar, R., & Khan, S. (2008). Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. Molecular and Cellular Endocrinology, 295(1–2), 70–78.PubMed
89.
Rayala, S. K., Talukder, A. H., Balasenthil, S., Tharakan, R., Barnes, C. J., Wang, R.-A., et al. (2006). P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Research, 66(3), 1694–1701.PubMed
90.
Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., et al. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486(7403), 346–352.PubMedPubMedCentral
91.
Mertins, P., Mani, D. R., Ruggles, K. V, Gillette, M. A., Clauser, K. R., Wang, P., et al. (2016). Proteogenomics connects somatic mutations to signalling in breast cancer. Nature, 534(7605), 55–62.
92.
Vadlamudi, R. K., Li, F., Barnes, C. J., Bagheri-Yarmand, R., & Kumar, R. (2004). p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Reports, 5(2), 154–160.PubMedPubMedCentral
93.
Molli, P. R., Li, D.-Q., Bagheri-Yarmand, R., Pakala, S. B., Katayama, H., Sen, S., et al. (2010). Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. The Journal of Cell Biology, 190(1), 101–114.PubMedPubMedCentral
94.
Sánchez-Solana, B., Motwani, M., Li, D.-Q., Eswaran, J., & Kumar, R. (2012). p21-activated kinase-1 signaling regulates transcription of tissue factor and tissue factor pathway inhibitor. The Journal of Biological Chemistry, 287(47), 39291–39302.PubMedPubMedCentral
95.
Callow, M. G., Clairvoyant, F., Zhu, S., Schryver, B., Whyte, D. B., Bischoff, J. R., et al. (2002). Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. The Journal of Biological Chemistry, 277(1), 550–558.PubMed
96.
Gong, W., An, Z., Wang, Y., Pan, X., Fang, W., Jiang, B., & Zhang, H. (2009). P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration. International Journal of Cancer, 125(3), 548–555.PubMed
97.
Lee, S. R., Ramos, S. M., Ko, A., Masiello, D., Swanson, K. D., Lu, M. L., & Balk, S. P. (2002). AR and ER interaction with a p21-activated kinase (PAK6). Molecular Endocrinology (Baltimore, Md.), 16(1), 85–99.
98.
Heiser, L. M., Wang, N. J., Talcott, C. L., Laderoute, K. R., Knapp, M., Guan, Y., et al. (2009). Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biology, 10(3), R31.PubMedPubMedCentral
99.
Shrestha, Y., Schafer, E. J., Boehm, J. S., Thomas, S. R., He, F., Du, J., et al. (2012). PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene, 31(29), 3397–3408.PubMed
100.
Arias-Romero, L. E., Villamar-Cruz, O., Pacheco, A., Kosoff, R., Huang, M., Muthuswamy, S. K., et al. (2010). A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene, 29(43), 5839–5849.PubMedPubMedCentral
101.
Liu, Y., Chen, N., Cui, X., Zheng, X., Deng, L., Price, S., et al. (2010). The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis. Oncogene, 29(44), 5883–5894.PubMedPubMedCentral
102.
Puto, L. A., Pestonjamasp, K., King, C. C., & Bokoch, G. M. (2003). p21-activated kinase 1 (PAK1) interacts with the Grb2 adapter protein to couple to growth factor signaling. The Journal of Biological Chemistry, 278(11), 9388–9393.PubMed
103.
Ohshiro, K., Bui-Nguyen, T. M., Divijendra Natha, R. S., Schwartz, A. M., Levine, P., & Kumar, R. (2012). Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway. The International Journal of Biological Markers, 27(4), e305–e313.PubMedPubMedCentral
104.
Long, W., Yi, P., Amazit, L., LaMarca, H. L., Ashcroft, F., Kumar, R., et al. (2010). SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Molecular Cell, 37(3), 321–332.PubMedPubMedCentral
105.
Ueda, Y., Wang, S., Dumont, N., Yi, J. Y., Koh, Y., & Arteaga, C. L. (2004). Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. The Journal of Biological Chemistry, 279(23), 24505–24513.PubMed
106.
Vadlamudi, R. K., Li, F., Adam, L., Nguyen, D., Ohta, Y., Stossel, T. P., & Kumar, R. (2002). Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nature Cell Biology, 4(9), 681–690.PubMed
107.
Wang, S. E., Shin, I., Wu, F. Y., Friedman, D. B., & Arteaga, C. L. (2006). HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Research, 66(19), 9591–9600.PubMed
108.
Rafn, B., Nielsen, C. F., Andersen, S. H., Szyniarowski, P., Corcelle-Termeau, E., Valo, E., et al. (2012). ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Molecular Cell, 45(6), 764–776.PubMed
109.
Brix, D. M., Tvingsholm, S. A., Hansen, M. B., Clemmensen, K. B., Ohman, T., Siino, V., et al. (2019). Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion. Oncogene, 38(17), 3170–3184.PubMedPubMedCentral
110.
Motwani, M., Li, D.-Q., Horvath, A., & Kumar, R. (2013). Identification of novel gene targets and functions of p21-activated kinase 1 during DNA damage by gene expression profiling. PLoS One, 8(8), e66585.PubMedPubMedCentral
111.
Berger, A., Hoelbl-Kovacic, A., Bourgeais, J., Hoefling, L., Warsch, W., Grundschober, E., et al. (2014). PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia, 28(3), 629–641.PubMed
112.
Chatterjee, A., Ghosh, J., Ramdas, B., Mali, R. S., Martin, H., Kobayashi, M., et al. (2014). Regulation of Stat5 by FAK and PAK1 in oncogenic FLT3- and KIT-driven leukemogenesis. Cell Reports, 9(4), 1333–1348.PubMedPubMedCentral
113.
Meng, Q., Rayala, S. K., Gururaj, A. E., Talukder, A. H., O’Malley, B. W., & Kumar, R. (2007). Signaling-dependent and coordinated regulation of transcription, splicing, and translation resides in a single coregulator, PCBP1. Proceedings of the National Academy of Sciences of the United States of America, 104(14), 5866–5871.PubMedPubMedCentral
114.
Li, Y., Shao, Y., Tong, Y., Shen, T., Zhang, J., Li, Y., et al. (2012). Nucleo-cytoplasmic shuttling of PAK4 modulates β-catenin intracellular translocation and signaling. Biochimica et Biophysica Acta, 1823(2), 465–475.PubMed
115.
Oladimeji, P., & Diakonova, M. (2016). PAK1 translocates into nucleus in response to prolactin but not to estrogen. Biochemical and Biophysical Research Communications, 473(1), 206–211.PubMedPubMedCentral
116.
Pérez-Yépez, E. A., Saldívar-Cerón, H. I., Villamar-Cruz, O., Pérez-Plasencia, C., & Arias-Romero, L. E. (2018). p21 activated kinase 1: Nuclear activity and its role during DNA damage repair. DNA Repair, 65, 42–46.PubMed
117.
Siu, M. K. Y., Kong, D. S. H., Ngai, S. Y. P., Chan, H. Y., Jiang, L., Wong, E. S. Y., et al. (2015). p21-activated kinases 1, 2 and 4 in endometrial cancers: Effects on clinical outcomes and cell proliferation. PLoS One, 10(7), e0133467.PubMedPubMedCentral
118.
Zhu, G., Wang, Y., Huang, B., Liang, J., Ding, Y., Xu, A., & Wu, W. (2012). A Rac1/PAK1 cascade controls β-catenin activation in colon cancer cells. Oncogene, 31(8), 1001–1012.PubMed
119.
Park, M.-H., Kim, D.-J., You, S.-T., Lee, C.-S., Kim, H. K., Park, S. M., et al. (2012). Phosphorylation of β-catenin at serine 663 regulates its transcriptional activity. Biochemical and Biophysical Research Communications, 419(3), 543–549.PubMed
120.
Ding, Q., Xia, W., Liu, J.-C., Yang, J.-Y., Lee, D.-F., Xia, J., et al. (2005). Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Molecular Cell, 19(2), 159–170.PubMed
121.
Arias-Romero, L. E., Villamar-Cruz, O., Huang, M., Hoeflich, K. P., & Chernoff, J. (2013). Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells. Cancer Research, 73(12), 3671–3682.PubMedPubMedCentral
122.
Adam, L., Vadlamudi, R. K., McCrea, P., & Kumar, R. (2001). Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta -catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. The Journal of Biological Chemistry, 276(30), 28443–28450.PubMed
123.
Bagheri-Yarmand, R., Vadlamudi, R. K., Wang, R. A., Mendelsohn, J., & Kumar, R. (2000). Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. The Journal of Biological Chemistry, 275(50), 39451–39457.PubMed
124.
Barnes, C. J., Vadlamudi, R. K., Mishra, S. K., Jacobson, R. H., Li, F., & Kumar, R. (2003). Functional inactivation of a transcriptional corepressor by a signaling kinase. Nature Structural Biology, 10(8), 622–628.PubMed
125.
Thomas, J.-L., Moncollin, V., Ravel-Chapuis, A., Valente, C., Corda, D., Méjat, A., & Schaeffer, L. (2015). PAK1 and CtBP1 regulate the coupling of neuronal activity to muscle chromatin and gene expression. Molecular and Cellular Biology, 35(24), 4110–4120.PubMedPubMedCentral
126.
Yang, Z., Rayala, S., Nguyen, D., Vadlamudi, R. K., Chen, S., & Kumar, R. (2005). Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail’s subcellular localization and functions. Cancer Research, 65(8), 3179–3184.PubMed
127.
Vadlamudi, R. K., Manavathi, B., Singh, R. R., Nguyen, D., Li, F., & Kumar, R. (2005). An essential role of Pak1 phosphorylation of SHARP in Notch signaling. Oncogene, 24(28), 4591–4596.PubMed
128.
Roig, J., & Traugh, J. A. (1999). p21-activated protein kinase gamma-PAK is activated by ionizing radiation and other DNA-damaging agents. Similarities and differences to alpha-PAK. The Journal of Biological Chemistry, 274(44), 31119–31122.PubMed
129.
Li, D.-Q., Nair, S. S., Ohshiro, K., Kumar, A., Nair, V. S., Pakala, S. B., et al. (2012). MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response. Cell Reports, 2(6), 1657–1669.PubMedPubMedCentral
130.
Advani, S. J., Camargo, M. F., Seguin, L., Mielgo, A., Anand, S., Hicks, A. M., et al. (2015). Kinase-independent role for CRAF-driving tumour radioresistance via CHK2. Nature Communications, 6, 8154.PubMedPubMedCentral
131.
Millan-Zambrano, G., Santos-Rosa, H., Puddu, F., Robson, S. C., Jackson, S. P., & Kouzarides, T. (2018). Phosphorylation of histone H4T80 triggers DNA damage checkpoint recovery. Molecular Cell, 72(4), 625–635.e4.PubMedPubMedCentral
132.
Tsai, C.-F., Wang, Y.-T., Yen, H.-Y., Tsou, C.-C., Ku, W.-C., Lin, P.-Y., et al. (2015). Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nature Communications, 6, 6622.PubMedPubMedCentral
133.
134.
Chen, T., Wang, T., Liang, W., Zhao, Q., Yu, Q., Ma, C.-M., et al. (2019). PAK4 phosphorylates fumarase and blocks TGFβ-induced cell growth arrest in lung cancer cells. Cancer Research, 79(7), 1383–1397.PubMed
135.
Jiang, Y., Qian, X., Shen, J., Wang, Y., Li, X., Liu, R., et al. (2015). Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nature Cell Biology, 17(9), 1158–1168.PubMedPubMedCentral
136.
Sedelnikova, O. A., & Bonner, W. M. (2006). GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle (Georgetown, Texas), 5(24), 2909–2913.
137.
Brustmann, H., Hinterholzer, S., & Brunner, A. (2011). Expression of phosphorylated histone H2AX (γ-H2AX) in normal and neoplastic squamous epithelia of the uterine cervix: An immunohistochemical study with epidermal growth factor receptor. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists, 30(1), 76–83.
138.
Matthaios, D., Foukas, P. G., Kefala, M., Hountis, P., Trypsianis, G., Panayiotides, I. G., et al. (2012). γ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. Oncotargets and Therapy, 5, 309–314.PubMedPubMedCentral
139.
Brunner, A. H., Hinterholzer, S., Riss, P., Heinze, G., Weiss, K., & Brustmann, H. (2011). Expression of γ-H2AX in endometrial carcinomas: An immunohistochemical study with p53. Gynecologic Oncology, 121(1), 206–211.PubMed
140.
Nagelkerke, A., van Kuijk, S. J. A., Sweep, F. C. G. J., Nagtegaal, I. D., Hoogerbrugge, N., Martens, J. W. M., et al. (2011). Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 101(1), 39–45.
141.
Gan, J., Zhang, Y., Ke, X., Tan, C., Ren, H., Dong, H., et al. (2015). Dysregulation of PAK1 is associated with DNA damage and is of prognostic importance in primary esophageal small cell carcinoma. International Journal of Molecular Sciences, 16(6), 12035–12050.PubMedPubMedCentral
142.
Qing, H., Gong, W., Che, Y., Wang, X., Peng, L., Liang, Y., et al. (2012). PAK1-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 33(4), 985–994.
143.
Walsh, K., McKinney, M. S., Love, C., Liu, Q., Fan, A., Patel, A., et al. (2013). PAK1 mediates resistance to PI3K inhibition in lymphomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(5), 1106–1115.
144.
Zhou, W., Jubb, A. M., Lyle, K., Xiao, Q., Ong, C. C., Desai, R., et al. (2014). PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. The Journal of Pathology, 234(4), 502–513.PubMedPubMedCentral
145.
Villamar Cruz, O., Prudnikova, T. Y., Araiza-Olivera, D., Perez-Plasencia, C., Johnson, N., Bernhardy, A. J., et al. (2016). Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition. Oncotarget, 7(47), 76590–76603.PubMed
146.
147.
Moon, S.-U., Kim, J. W., Sung, J. H., Kang, M. H., Kim, S.-H., Chang, H., et al. (2015). p21-activated kinase 4 (PAK4) as a predictive marker of gemcitabine sensitivity in pancreatic cancer cell lines. Cancer Research and Treatment : Official Journal of Korean Cancer Association, 47(3), 501–508.
148.
Li, D., Yao, X., & Zhang, P. (2013). The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer. Molecular and Cellular Biochemistry, 383(1–2), 191–199.PubMed
149.
He, S., Feng, M., Liu, M., Yang, S., Yan, S., Zhang, W., et al. (2014). P21-activated kinase 7 mediates cisplatin-resistance of esophageal squamous carcinoma cells with Aurora-A overexpression. PLoS One, 9(12), e113989.PubMedPubMedCentral
150.
Chen, J., Lu, H., Yan, D., Cui, F., Wang, X., Yu, F., et al. (2015). PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy. Oncotarget, 6(1), 355–367.PubMed
151.
Huynh, N., Shulkes, A., Baldwin, G., & He, H. (2016). Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer. Cancer Biology & Therapy, 17(8), 813–823.
152.
Yeo, D., He, H., Patel, O., Lowy, A. M., Baldwin, G. S., & Nikfarjam, M. (2016). FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer, 16, 24.PubMedPubMedCentral
153.
Chang, Y., Park, K. H., Lee, J. E., & Han, K.-C. (2018). Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells. Biochemical and Biophysical Research Communications, 505(1), 187–193.PubMed
154.
Flis, S., Bratek, E., Chojnacki, T., Piskorek, M., & Skorski, T. (2019). Simultaneous inhibition of BCR-ABL1 tyrosine kinase and PAK1/2 serine/threonine kinase exerts synergistic effect against chronic myeloid leukemia cells. Cancers, 11(10). https://​doi.​org/​10.​3390/​cancers11101544.
155.
Korobeynikov, V., Borakove, M., Feng, Y., Wuest, W. M., Koval, A. B., Nikonova, A. S., et al. (2019). Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Breast Cancer Research and Treatment, 177(2), 369–382.PubMedPubMedCentral
156.
Khan, H. Y., Ge, J., Nagasaka, M., Aboukameel, A., Mpilla, G., Muqbil, I., et al. (2019). Targeting XPO1 and PAK4 in 8505C anaplastic thyroid cancer cells: Putative implications for overcoming lenvatinib therapy resistance. International Journal of Molecular Sciences, 21(1). https://​doi.​org/​10.​3390/​ijms21010237.
157.
158.
Li, N., Lopez, M. A., Linares, M., Kumar, S., Oliva, S., Martinez-Lopez, J., et al. (2019). Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenström Macroglobulinemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 25(1), 369–377.
159.
Zhang, M., Siedow, M., Saia, G., & Chakravarti, A. (2010). Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells. The Prostate, 70(8), 807–816.PubMedPubMedCentral
160.
Wang, K., Huynh, N., Wang, X., Pajic, M., Parkin, A., Man, J., et al. (2019). PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines. American Journal of Translational Research, 11(6), 3353–3364.PubMedPubMedCentral
161.
Abril-Rodriguez, G., Torrejon, D. Y., Liu, W., et al. (2020). PAK4 inhibition improves PD-1 blockade immunotherapy. Nature Cancer, 1(1), 46–58.
162.
Ong, C. C., Jubb, A. M., Jakubiak, D., Zhou, W., Rudolph, J., Haverty, P. M., et al. (2013). P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. Journal of the National Cancer Institute, 105(9), 606–607.PubMed
163.
Babagana, M., Johnson, S., Slabodkin, H., Bshara, W., Morrison, C., & Kandel, E. S. (2017). P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. Molecular Carcinogenesis, 56(5), 1515–1525.PubMedPubMedCentral
164.
Araiza-Olivera, D., Feng, Y., Semenova, G., Prudnikova, T. Y., Rhodes, J., & Chernoff, J. (2018). Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene, 37(7), 944–952.PubMed
165.
Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., et al. (2013). Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discovery, 3(5), 520–533.PubMedPubMedCentral
166.
Kugel 3rd, C. H., Hartsough, E. J., Davies, M. A., Setiady, Y. Y., & Aplin, A. E. (2014). Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Research, 74(15), 4122–4132.PubMedPubMedCentral
167.
Kaneko, M., Saito, Y., Saito, H., Matsumoto, T., Matsuda, Y., Vaught, J. L., et al. (1997). Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. Journal of Medicinal Chemistry, 40(12), 1863–1869.PubMed
168.
Zhu, J., Huang, J.-W., Tseng, P.-H., Yang, Y.-T., Fowble, J., Shiau, C.-W., et al. (2004). From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Research, 64(12), 4309–4318.PubMed
169.
170.
Ndubaku, C., & Tsui, V. (2015). Inhibiting the deubiquitinating enzymes (DUBs). Journal of Medicinal Chemistry, 58(4), 1581–1595.PubMed
171.
Rudolph, J., Murray, L. J., Ndubaku, C. O., O’Brien, T., Blackwood, E., Wang, W., et al. (2016). Chemically diverse group I p21-activated kinase (PAK) inhibitors impart acute cardiovascular toxicity with a narrow therapeutic window. Journal of Medicinal Chemistry, 59(11), 5520–5541.PubMed
172.
Kim, D.-J., Choi, C.-K., Lee, C.-S., Park, M.-H., Tian, X., Kim, N. D., et al. (2016). Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain. Experimental & Molecular Medicine, 48(4), e229. https://​doi.​org/​10.​1038/​emm.​2016.​13.CrossRef
173.
Fattore, L., Marra, E., Pisanu, M. E., Noto, A., de Vitis, C., Belleudi, F., et al. (2013). Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. Journal of Translational Medicine, 11, 180.PubMedPubMedCentral
174.
Herr, R., Halbach, S., Heizmann, M., Busch, H., Boerries, M., & Brummer, T. (2018). BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene, 37(12), 1576–1593.PubMed
175.
Cruz, O. V., Prudnikova, T. Y., Araiza-Olivera, D., Perez-Plasencia, C., Johnson, N., Bernhardy, A. J., et al. (2016). Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition. Oncotarget, 7(47), 76590–76603.PubMedCentral
176.
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., et al. (2012). The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discovery, 2(5), 401–404.PubMed
177.
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling, 6, l1.
Metadata
Title
Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases
Authors
Rakesh Kumar
Aswathy Mary Paul
Ravikumar Amjesh
Bijesh George
M. Radhakrishna Pillai
Publication date
01-09-2020
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2020
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-020-09922-6

Other articles of this Issue 3/2020

Cancer and Metastasis Reviews 3/2020 Go to the issue

ReviewPaper

BRMS1: a multifunctional signaling molecule in metastasis

Commentary

Role of linoleic acid-derived oxylipins in cancer

Non-Thematic Review

Brain tumor vessels—a barrier for drug delivery

ReviewPaper

Molecular and cellular mechanisms underlying brain metastasis of breast cancer

ReviewPaper

FOXO transcription factor family in cancer and metastasis

ReviewPaper

Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits